On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical ...

Life sciences and specialty diagnostics giant Thermo Fisher Scientific Inc. (NYSE: TMO) said it has received a $94.5 million contract to supply the U.S. Navy with advanced radiation detection systems, ...

Ethris has entered a strategic partnership with Thermo Fisher Scientific to provide a completely integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers. The partnership ...

Thermo Fisher Scientific (NYSE:TMO) recently made headlines by entering a collaboration with Ethris GmbH to advance mRNA solutions and putting a $4 billion price tag on part of its diagnostics ...

(Reuters) -Thermo Fisher Scientific plans to sell its diagnostics unit for about $4 billion in an attempt to offload some of its low-growth assets, the Financial Times reported on Thursday, citing ...

Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary. Read why TMO stock is a Strong Buy.

Thermo Fisher launches the Orbitrap Astral Zoom and Orbitrap Excedion Pro MS at ASMS 2025, advancing proteomics and drug development.

Thermo Fisher introduces next-gen mass spectrometry solutions at ASMS, designed to accelerate research in multiple scientific fields.

Thermo Fisher Scientific, a Massachusetts-based CDMO giant, inked a collaboration deal with biotech startup Mirai Bio to develop and manufacture new gene therapies.

Thermo Fisher Scientific announced a $2 billion investment in US operations over the next four years to bolster domestic innovation and manufacturing capabilities in the life sciences sector.

Conclusion Thermo Fisher was priced for perfection in January near $600, and we got a lot of imperfection in the form of slow growth plus tariff and fiscal policy headwinds.

Thermo Fisher cut its 2025 EPS and revenue outlook due to tariffs and U.S. policy changes, expecting a $400 million sales hit and lower operating income.